pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

TAG: NSCLC

Sep 28, 2023

First Patient Dosed in Phase 1b Clinical Trial of Synthekine’s α/β Biased IL-2, STK-012, for Treatment of Solid Tumors

Apr 11, 2023

MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

Apr 4, 2023

Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer

Apr 3, 2023

Scorpion Therapeutics Nominates STX-241 as Potentially Best-in-Class Fourth-Generation EGFR Inhibitor Development Candidate for the Treatment of Non-Small Cell Lung Cancer

Mar 7, 2023

MAIA Biotechnology Doses First Patients in Europe in Ongoing Phase 2 Trial (THIO-101) Evaluating THIO for Non-Small Cell Lung Cancer Treatment

Mar 1, 2023

GenFleet receives EMA approval for phase Ib/II study of GFH925 (KRAS G12C inhibitor) in combination with ERBITUX (cetuximab) treating patients with advanced NSCLC in first-line setting

Jan 5, 2023

Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer

Dec 20, 2022

MAIA Biotechnology Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

Dec 13, 2022

MAIA Biotechnology Expands Phase 2 THIO-101 Trial to Europe

Nov 10, 2022

Galvanize Therapeutics Presents Clinical Data Using Pulsed Electric Field (PEF) Energy for Non-Small Cell Lung Cancer

Sep 27, 2022

SEngine Precision Medicine Announces New Non-Small Cell Lung Cancer Study at Johns Hopkins University

Aug 29, 2022

NEXT-GENERATION EGFR TKI H002 FROM REDCLOUD BIO COMPLETES FIRST DOSE IN NON-SMALL CELL LUNG CANCER

Jul 18, 2022

MAIA Biotechnology Doses First Patient With THIO in Phase 2 Trial (THIO-101) for Non-Small Cell Lung Cancer

Jul 5, 2022

ArriVent Biopharma Announces First Patient Enrolled in Global Phase 1b Trial of Furmonertinib in Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR or HER2 Mutations

Jun 29, 2022

Scorpion Therapeutics Nominates STX-721 as EGFR-EXON-20 Development Candidate with a Best-in-Class Profile

Jun 7, 2022

EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso for Non-Small Cell Lung Cancer

Mar 15, 2022

MAIA Biotechnology, Inc. Announces HREC Approval in Australia for its THIO-101 Phase 2 Trial for NSCLC

Mar 2, 2022

REDCLOUD BIO ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR NEXT-GENERATION EGFR INHIBITOR H002 IN NON-SMALL CELL LUNG CANCER

Feb 28, 2022

Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer

Jan 9, 2022

Laekna Therapeutics and Innovent Biologics obtain IND approval for combination therapy in patients with specific types of solid tumors who have been refractory to treatment with PD-1/PD-L1 inhibitors

Dec 22, 2021

Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy

Dec 9, 2021

Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Combination with Osimertinib in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer

Nov 8, 2021

NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in Combination with PD-L1 Checkpoint Inhibitor in Frontline Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Oct 4, 2021

Himalaya Therapeutics Announces Submission in Mainland China of IND Applications for its CAB-AXL-ADC to treat sarcomas and NSCLC, its CAB-ROR2-ADC to treat melanoma and NSCLC

Sep 26, 2021

Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting

Aug 16, 2021

Immunicom Continues Successful Immunopheresis Clinical Trial in Advanced, Non-Small Cell Lung Cancer Treatment with Acibadem University

Aug 4, 2021

eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer

Jun 6, 2021

AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

May 19, 2021

AnHeart Announces Upcoming Presentation of Preliminary Results from Phase II Trial of Taletrectinib in ROS1+ NSCLC at the ASCO 2021 Virtual Meeting

Apr 13, 2021

Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors

Feb 16, 2021

Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings

Feb 2, 2021

MAIA Biotechnology, Inc. Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating THIO in Sequential Administration with Libtayo (cemiplimab) in Advanced Non-Small Cell Lung Cancer

Jan 28, 2021

ImmunityBio Announces Positive Phase 2 Results Showing That Anktiva Restores the Activity of Checkpoint Inhibitors in Patients Who Have Relapsed Checkpoint Immunotherapy in Non-Small Cell Lung Cancer

Jan 6, 2021

TRIGR Therapeutics Announces Publication of TR009/ABL001, Dual Angiogenic Bispecific Antibody Targeting VEGF/DLL4, in the International Journal of Molecular Sciences

Nov 16, 2020

NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 2 Study of NT-I7 (efineptakin alfa) in combination with PD-L1 checkpoint inhibitor in First-line Non-small Cell Lung Cancer

Oct 29, 2020

AnHeart Announces Publication of Pooled Analysis of two Phase 1 Studies of Taletrectinib in ROS1+ NSCLC

Oct 21, 2020

NeoImmuneTech Announces a Second Clinical Collaboration with Roche to Evaluate NT-I7 (efineptakin alfa) in Combination with PD-L1 checkpoint inhibitor in First-line Non-small Cell Lung Cancer

Sep 30, 2020

Verastem Oncology Announces Closing of COPIKTRA (duvelisib) Sale to Secura Bio

Aug 3, 2020

PharmAbcine signs a research collaboration agreement with Wuxi Shuangliang Biotechnology (SLBio) to evaluate a combination therapy to treat NSCLC

Jul 28, 2020

Iterion Therapeutics Initiates Enrollment of Phase 2a Dose Expansion Study of Tegavivint in Patients with Desmoid Tumors

Jul 21, 2020

First Patient Dosed with Taletrectinib in AnHeart Phase 2 Trial of Non-Small Cell Lung Cancer with ROS1 Fusion

Jun 24, 2020

Grid Therapeutics Announces Enrollment of First Patient in Phase 1 Study of GT103 in Refractory NSCLC Patients

Jun 1, 2020

Biomarck Pharmaceuticals to Present Expanded Analysis of BIO-11006 Clinical Data in Treatment of Non-Small Cell Lung Cancer at the American Thoracic Society 2020 International Conference

May 28, 2020

WindMIL Therapeutics Announces Dosing of First Patient in Phase 2 Clinical Study of MILs™ - NSCLC in Combination with Nivolumab (Opdivo) for the Treatment of Non-Small Cell Lung Cancer

May 21, 2020

WindMIL Therapeutics Opens Combination Therapy Portion of its Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer

Apr 14, 2020

Grid Therapeutics Announces FDA Approval of IND Application for GT103

Feb 25, 2020

IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer

Dec 19, 2019

WindMIL Therapeutics Announces Clinical Research Collaboration with Bristol-Myers Squibb to Evaluate Marrow-Infiltrating Lymphocytes (MILs™) in Combination with nivolumab (Opdivo) for Treatment of Patients with Non-Small Cell Lung Cancer

Dec 12, 2019

WindMIL Therapeutics Announces Dosing of First Patient in a Phase 2a Clinical Trial of Marrow-Infiltrating Lymphocytes (MILs™) for Treatment of Patients with Non-Small Cell Lung Cancer

Sep 9, 2019

KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients USA - English USA - English

Sep 9, 2019

KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients

Jul 16, 2019

Cyclica and University of Toronto Stagljar Lab Announce Partnership to Create the Next-Generation EGFR Inhibitors in Non-Small Cell Lung Cancer

Jun 25, 2019

WindMIL Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 2 Study of Marrow Infiltrating Lymphocytes (MILs™) in Non-Small Cell Lung Cancer

May 15, 2019

IO Biotech Initiates Global Phase 2 Portion of Clinical Trial For T-win® Immunotherapy in Non-small Cell Lung Cancer

Apr 17, 2019

SK Biopharmaceuticals and twoXAR Sign Collaboration Agreement to Discover and Develop First-In-Class Treatments for Non-Small Cell Lung Cancer

Apr 2, 2019

Aro Biotherapeutics to Present Data on Lead Program, ABX900, at AACR

Mar 13, 2019

Global Non-Small Cell Lung Cancer Pipeline Therapeutics Report 2019 - ResearchAndMarkets.com

Dec 28, 2018

InventisBio and Betta Pharma to Co-Develop Novel Drug for Non-Small Cell Lung Cancer

Dec 10, 2018

CBT Pharmaceuticals and Strata Oncology Announce Collaboration to Accelerate Development of CBT-101, a c-Met inhibitor, for Patients with Non-Small Cell Lung Cancer and other Solid Tumors

Oct 22, 2018

Forbius Announces First Patient Dosed in Phase 2 Trial of anti-EGFR ADC AVID100 in EGFR-Overexpressing Squamous NSCLC

Sep 27, 2018

IO Biotech announces first patient dosed in global phase I/II clinical trial for the first-line treatment of patients with metastatic non-small cell lung cancer

Aug 1, 2018

Xcovery Announces First Cohort of Patients Dosed in a Phase 1/2 Clinical Trial of Vorolanib in Combination with Nivolumab for Treatment of Non-Small Cell Lung Cancer or Thymic Carcinoma

Jun 14, 2018

Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy

May 24, 2018

Checkmate Pharmaceuticals Announces Start of Phase 1b Trial of CMP-001 in Combination with Anti-PD-L1 Immunotherapy in Anti-PD-1/PD-L1 Resistant Advanced Non-Small Cell Lung Cancer

Mar 12, 2018

IO Biotech enters clinical collaboration with MSD evaluating IO102 in combination with KEYTRUDA® (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer

Nov 7, 2017

Pique Therapeutics Announces Positive Results in Phase 2 Clinical Trial of Lead Immunotherapy for Non-Small Cell Lung Cancer

Sep 13, 2017

CrownBio’s Integrated Oncology Platform Helps Advance Apogenix’s Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer

Jul 19, 2017

Biothera Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA in Non-Small Cell Lung Cancer

Jul 17, 2017

Apexigen, Inc. Announces First Patient Dosed in Phase 1b/2 Clinical Trial of APX005M in Combination with Opdivo (nivolumab) in Advanced Solid Tumors

Feb 1, 2017

Hope Biosciences Acquires Worldwide Rights To Novel MERTK/AXL Inhibitor From NeoPharm

Aug 24, 2016

Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications

Aug 11, 2016

Global Non-Small Cell Lung Cancer Pipeline Review, H1 2016 - Analysis, Technologies and Forecasts Report - Key Vendors: 4SC, AbbVie, HitGen - Research and Markets

Jun 29, 2016

Xcovery Announces Initiation of Phase 3 Trial of X-396 in ALK+ Non-Small Cell Lung Cancer

May 20, 2016

Xcovery Presents Data Supporting the Potential Efficacy of X-396 in Patients with ALK+ Non-Small Cell Lung Cancer at the AACR Annual Meeting 2016

Jan 8, 2016

Xcovery Announces Updated Clinical Data on X-396 in Patients with ALK+ Non-Small Cell Lung Cancer at the 4th AACR-IASLC International Joint Conference

Jan 5, 2016

Xcovery to Present X-396 in ALK+ Non-Small Cell Lung Cancer Study Data at 4th Annual AACR-IASLC International Joint Conference

Jan 20, 2015

Qu Biologics Launches Phase 2a Clinical Trial for Non-small Cell Lung Cancer (NSCLC)

Oct 31, 2014

Xcovery Presents Phase 1 Results of X-396 in ALK positive NSCLC at the 2014 Multidisciplinary Symposium in Thoracic Oncology

Jun 3, 2014

Xcovery Presents Interim Phase 1 Results of X-396 in ALK positive NSCLC at the American Society for Clinical Oncology Annual Meeting

Sep 7, 2012

The SFJ Pharmaceuticals Group Announces Agreement With Pfizer to Co-develop Dacomitinib as First-Line Treatment for Patients With Advanced Non-small Cell Lung Cancer